Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 13/20 | 0.64 |
| ▸ | AHR | P35869 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 2/20 | 0.53 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.53 |
| ▸ | IDO1 | P14902 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28865546 | 0.98 | GAA (0.62) | GAAAHRKMT2AMEN1SMN1; SMN2 | |
| Dimethylformamide SCHEMBL27577776 | 0.89 | GAA (0.53) | GAAAHRKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL4712443 | 0.85 | PKM (0.57) | PKMIDO1 | |
| Hydrochloric Acid SCHEMBL28787666 | 0.83 | PKM (0.56) | PKMIDO1 | |
| SCHEMBL6423157 | 0.83 | GAA (0.57) | GAAKMT2AMEN1SMN1; SMN2SMYD3 | |
| SCHEMBL689168 | 0.83 | GAA (0.60) | GAAAHRPKMSMYD3IDO1 | |
| SCHEMBL1556955 | 0.83 | GAA (0.60) | GAAAHRKMT2APKMSMYD3 | |
| SCHEMBL10293161 | 0.83 | GAA (0.60) | GAAAHRKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL517067 | 0.83 | GAA (0.60) | GAAAHRKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL6423152 | 0.82 | GAA (0.56) | GAAKMT2AMEN1SMN1; SMN2SMYD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1684744-A4 | PYRROLIDINE AND PIPERIDINE DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2008-12-17 | — | — | EP | claimed |
| EP-1684744-A2 | PYRROLIDINE AND PIPERIDINE DERIVATIVES AS FACTOR XA INHIBITORS | Bristol-Myers Squibb Company (US) | 2006-08-02 | — | — | EP | claimed |
| US-20050119266-A1 | Pyrrolidine and piperidine derivatives as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-06-02 | — | — | US | claimed |
| WO-2005032472-A2 | PYRROLIDINE AND PIPERIDINE DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-04-14 | — | — | WO | claimed |
| US-20040147586-A1 | Indolinone derivatives as protein kinase/phosphatase inhibitors | SUGEN, INC. | 2004-07-29 | — | — | US | claimed |
| EP-1294688-A2 | INDOLINONE DERIVATIVES AS PROTEIN KINASE/PHOSPHATASE INHIBITORS | Sugen, Inc. (US) | 2003-03-26 | — | — | EP | claimed |
| US-20020052369-A1 | Indolinone derivatives as protein kinase/phosphatase inhibitors | SUGEN, INC. | 2002-05-02 | — | — | US | claimed |
| WO-2001094312-A2 | INDOLINONE DERIVATIVES AS PROTEIN KINASE/PHOSPHATASE INHIBITORS | SUGEN, INC. (US) | 2001-12-13 | — | — | WO | claimed |
| US-8461134-B2 | Boron-containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-7981880-B2 | 3-(aminomethyliden) 2-indolinone derivates and their use as cell proliferation inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-19 | — | — | US | disclosed |
| US-7572924-B2 | Pyrrole substituted 2-indolinone protein kinase inhibitors | SUGEN, INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-20090105216-A1 | 3- (AMINOMETHYLIDEN) 2-INDOLINONE DERIVATES AND THEIR USE AS CELL PROLIFERATION INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-23 | — | — | US | disclosed |
| EP-1684744-A4 | PYRROLIDINE AND PIPERIDINE DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2008-12-17 | — | — | EP | disclosed |
| US-7320996-B2 | Indolinone protein kinase inhibitors and cyclooxygenase inhibitors for use in combination therapy for the treatment of cancer | SUGEN, INC (US) | 2008-01-22 | — | — | US | disclosed |
| US-5840745-A | INHIBITING CELL PROLIFERATION, TUMOR GROWTH, METASTASIS, DEVELOPMENT OF ATHEROMATOUS PLAQUE AND RESTENOSIS, CONTROLLING ANGIOGENESIS, TREATING DIABETES, ENHANCING CANCER THERAPY | PHARMACIA S. P. A. (IT) | 1998-11-24 | — | — | US | disclosed |
| US-5663346-A | ENZYME INHIBITORS | PHARMACIA S.P.A. (IT) | 1997-09-02 | — | — | US | disclosed |
| EP-0752985-A1 | HYDROSOLUBLE 3-ARYLIDENE-2-OXINDOLE DERIVATIVES AS TYROSINE KINASE INHIBITORS | PHARMACIA & UPJOHN S.p.A. (IT) | 1997-01-15 | — | — | EP | disclosed |
| WO-1996022976-A1 | HYDROSOLUBLE 3-ARYLIDENE-2-OXINDOLE DERIVATIVES AS TYROSINE KINASE INHIBITORS | PHARMACIA S.P.A. (IT) | 1996-08-01 | — | — | WO | disclosed |
| EP-0715628-A1 | SUBSTITUTED AZAINDOLYLIDENE COMPOUNDS AND PROCESS FOR THEIR PREPARATION | PHARMACIA & UPJOHN S.p.A. (IT) | 1996-06-12 | — | — | EP | disclosed |
| WO-1996000226-A1 | SUBSTITUTED AZAINDOLYLIDENE COMPOUNDS AND PROCESS FOR THEIR PREPARATION | PHARMACIA S.P.A. (IT) | 1996-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119266-A1 | Pyrrolidine and piperidine derivatives as factor Xa inhibitors | PEPD, SERPINE1, PRSS1 | GAA 294/4885AHR 4474/4885KMT2A 2655/4885 |
| US-20040147586-A1 | Indolinone derivatives as protein kinase/phosphatase inhibitors | PHKA1, PHKA2, PDPK1 | GAA 714/4885AHR 2554/4885KMT2A 1656/4885 |
| US-20090105216-A1 | 3- (AMINOMETHYLIDEN) 2-INDOLINONE DERIVATES AND THEIR USE AS CELL PROLIFERATION INHIBITORS | MKI67, CCNI, CCNA1 | GAA 1880/4885AHR 254/4885KMT2A 1482/4885 |
| US-20020052369-A1 | Indolinone derivatives as protein kinase/phosphatase inhibitors | PHKA1, PHKA2, PDPK1 | GAA 714/4885AHR 2554/4885KMT2A 1656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.